Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601

Watchlist Manager
Shenzhen Kangtai Biological Products Co Ltd Logo
Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601
Watchlist
Price: 18.1 CNY -4.99% Market Closed
Market Cap: 20.2B CNY
Have any thoughts about
Shenzhen Kangtai Biological Products Co Ltd?
Write Note

Shenzhen Kangtai Biological Products Co Ltd
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Kangtai Biological Products Co Ltd
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601
Total Assets
ÂĄ14.4B
CAGR 3-Years
10%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Assets
ÂĄ41.1B
CAGR 3-Years
4%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Assets
ÂĄ15.7B
CAGR 3-Years
65%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Assets
ÂĄ32.4B
CAGR 3-Years
7%
CAGR 5-Years
23%
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Assets
ÂĄ54.8B
CAGR 3-Years
32%
CAGR 5-Years
43%
CAGR 10-Years
36%
Imeik Technology Development Co Ltd
SZSE:300896
Total Assets
ÂĄ6.9B
CAGR 3-Years
14%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Kangtai Biological Products Co Ltd
Glance View

Market Cap
20.2B CNY
Industry
Biotechnology

Shenzhen Kangtai Biological Products Co., Ltd. engages in the manufacture, sale, and research and development of human vaccines. The company is headquartered in Shenzhen, Guangdong and currently employs 2,445 full-time employees. The company went IPO on 2017-02-07. is a China-based company and mainly engaged in research and development, manufacture and sale of vaccine. The main products of the company are recombinant hepatitis B virus, haemophilus influenzae type b combined vaccine, measles rubella combined attenuated live vaccine, non-cell Bai Bai Po haemophilus influenzae combined vaccine and other products. The firm operates its businesses primary in domestic market.

Intrinsic Value
22.35 CNY
Undervaluation 19%
Intrinsic Value
Price

See Also

What is Shenzhen Kangtai Biological Products Co Ltd's Total Assets?
Total Assets
14.4B CNY

Based on the financial report for Jun 30, 2024, Shenzhen Kangtai Biological Products Co Ltd's Total Assets amounts to 14.4B CNY.

What is Shenzhen Kangtai Biological Products Co Ltd's Total Assets growth rate?
Total Assets CAGR 5Y
33%

Over the last year, the Total Assets growth was 1%. The average annual Total Assets growth rates for Shenzhen Kangtai Biological Products Co Ltd have been 10% over the past three years , 33% over the past five years .

Back to Top